HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors

被引：48
|
作者：
Wainberg, MA [1 ]
机构：
[1] McGill Univ, AIDS Ctr, Jewish Gen Hosp, Montreal, PQ, Canada
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2003年 / 34卷
关键词：
nevirapine; NNRTI; resistance; HIV-1;
D O I：
10.1097/00126334-200309011-00002
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Nevirapine and other members of the non-nucleoside reverse transcriptase inhibitor (NNRTI) family of anti-HIV-1 drugs are essential components of antiretroviral treatment regimens. Unfortunately, drug resistance has become an important issue with respect to all therapeutic targets in HIV-1. This paper summarizes current knowledge about the mutations in the reverse transcriptase gene of HIV-1 that are responsible for drug resistance and the mechanisms whereby drug resistance develops.
引用
收藏
页码：S2 / S7
页数：6
相关论文
共 50 条
  • [21] A new insertion in the HIV-1 reverse transcriptase gene inducing major resistance to non-nucleoside reverse transcriptase inhibitors
    Amiel, C
    Desire, N
    Schneider, V
    Delphin, N
    Race, E
    Clavel, F
    Piolot, T
    Dam, E
    Rozenbaum, W
    Nicolas, JC
    AIDS, 2005, 19 (16) : 1922 - 1924
  • [22] Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?
    Morlese, JF
    Qazi, NA
    Gazzard, BG
    Nelson, MR
    AIDS, 2002, 16 (13) : 1840 - 1841
  • [23] A novel molecular mechanism of dual resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors
    Nikolenko, G. N.
    Delviks-Frankenberry, K. A.
    Pathak, V. K.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A33 - A33
  • [24] Clinical experience with non-nucleoside reverse transcriptase inhibitors: L697,661 and nevirapine
    Kilby, JM
    Saag, MS
    ANTIVIRAL CHEMOTHERAPY 4: NEW DIRECTIONS FOR CLINICAL APPLICATION AND RESEARCH, 1996, 394 : 291 - 298
  • [25] Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
    Himmel, Daniel M.
    Arnold, Eddy
    PHARMACEUTICALS, 2020, 13 (06) : 1 - 26
  • [26] The flourishing syntheses of non-nucleoside reverse transcriptase inhibitors
    Pedersen, OS
    Pedersen, EB
    SYNTHESIS-STUTTGART, 2000, (04): : 479 - 495
  • [27] Conformational preferences of non-nucleoside HIV-1 reverse transcriptase inhibitors
    Parreira, RLT
    Abrahao, O
    Galembeck, SE
    TETRAHEDRON, 2001, 57 (16) : 3243 - 3253
  • [28] Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase
    Ruiz-Caro, J
    Basavapathruni, A
    Kim, JT
    Bailey, CM
    Wang, LG
    Anderson, KS
    Hamilton, AD
    Jorgensen, WL
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (03) : 668 - 671
  • [29] Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors
    Patrick F. Smith
    Robert DiCenzo
    Gene D. Morse
    Clinical Pharmacokinetics, 2001, 40 : 893 - 905
  • [30] Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1
    Chan, JH
    Freeman, GA
    Tidwell, JH
    Romines, KR
    Schaller, LT
    Cowan, JR
    Gonzales, SS
    Lowell, GS
    Andrews, CW
    Reynolds, DJ
    St Clair, M
    Hazen, RJ
    Ferris, RG
    Creech, KL
    Roberts, GB
    Short, SA
    Weaver, K
    Koszalka, GW
    Boone, LR
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (05) : 1175 - 1182
12345